Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
| Current Price | ₹204.24 |
|---|---|
| Market Cap | ₹6,628 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 4.3 |
| Return on Equity | 276.89% |
| Beta (1Y) | 0.88 |
1. Pharmaceuticals Research and Development-100%
Sun Pharma Advanced Research Company Limited (Sparc) is trading at ₹204.24, with a market capitalisation of ₹6,628 Cr.
Sun Pharma Advanced Research Company Limited (Sparc) operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Sun Pharma Advanced Research Company Limited (Sparc) has a P/E of 4.3 and a return on equity of 276.89%.